Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Tuberculosis burden attributable to smoking in China 1990–2021 and projections to 2040: A secondary analysis of GBD 2021 data

INTRODUCTION Smoking is a well-established modifiable risk factor for tuberculosis (TB). However, the evolving smoking-attributable TB burden in China remains to be fully characterized. The objective was to examine temporal trends in the smoking-attributable TB burden in China from 1990 to 2021. METHODS A secondary analysis was conducted on the 2021 Global Burden of Disease Study data. Data on the number of deaths and disability adjusted life years (DALYs) due to smoking-attributable TB, as well as age-standardized rates, were extracted for the overall Chinese population, males, and females from 1990 to 2021. Joinpoint regression and age-period-cohort analyses described 32-year trends. A Bayesian age-period-cohort (BAPC) model was used to forecast the TB burden from 2022 to 2040. Drivers behind the burden trends were investigated through a decomposition analysis. RESULTS Between 1990 and 2021, TB deaths, DALYs, age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) showed significant reductions, with the ASMR and ASDR declining from 5.10/100000 (95% UI: 3.64–6.73) and 158.48/100000 (95% UI: 114.49–203.94) in 1990 to 0.52/100000 (95% UI: 0.37–0.76) and 19.15/100000 (95% UI: 13.85–26.70) in 2021, respectively. Declines in ASMR (-95.26% vs -89.35%) and ASDR (-93.69% vs -87.35%) were larger in females than in males. Age-period-cohort analyses revealed that mortality and DALY rates peaked at ages 30–34 years and then declined. Male mortality increased slightly at ages 65–69 years. Both period and cohort effects demonstrated consistent downward trends. BAPC projections indicated that after 2022, deaths and DALYs would decline initially but rise again, whereas ASMR and ASDR would continue to fall. CONCLUSIONS The smoking-attributable TB burden in China exhibits significant age- and sex-specific patterns. Despite overall attenuation, projected rebounds in deaths by 2040 call for sustained public health interventions.

Feng Zhao, Tingyong Yan · 0 citations
Open access Jul 2026

Multi-omic discovery of SCG5 as a shared driver and prognostic biomarker in head-neck and non-small cell lung cancers

Patients with head and neck squamous cell carcinoma (HNSC) face a high risk of developing non-small cell lung cancer (NSCLC). However, the shared molecular drivers linking these two malignancies remain poorly defined. We integrated TCGA and GEO datasets to identify shared differentially expressed genes (DEGs) between HNSC and NSCLC, subsequently evaluating their prognostic value, immune infiltration patterns (ssGSEA), and enriched pathways. Clinical validation of SCG5 protein expression was comprehensively performed using tissue microarrays (TMA) via immunohistochemistry. in vitro assays, including siRNA-mediated knockdown, CCK-8, colony formation, and Western blotting, were conducted in both HNSC (SCC-25) and NSCLC (A549) cell lines to ascertain its oncogenic functions and underlying molecular mechanisms. SCG5 was identified as a consistently upregulated, independent predictor of poor survival in both cancers. IHC confirmed SCG5 protein overexpression, correlating with lymph node metastasis and advanced clinical stages. GSEA revealed that SCG5-associated genes were significantly enriched in focal adhesion and the PI3K/AKT signaling pathway in both HNSC and NSCLC. SCG5 expression correlated positively with tumor-infiltrating macrophages (P < 0.001) and with PDCD1LG2, HAVCR2 and SIGLEC15 (P < 0.05). SCG5 knockdown significantly suppressed cell proliferation and colony formation in both SCC-25 and A549 cells, concurrently attenuating PI3K and AKT phosphorylation. SCG5 is a novel shared oncogenic driver and prognostic biomarker for HNSC and NSCLC. Downregulation of SCG5 suppresses the growth of HNSC and NSCLC cells, potentially through modulating the PI3K/AKT signaling pathway, thereby presenting a potential therapeutic target for both malignancies.

Feng Zhao, Haining Wang, Tao Qin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.